سعر Metoject 10 mg/0.2 ml pre-filled syringe 2026

Metoject 10 mg/0.2 ml (methotrexate 50 mg/ml) solution for injection in a pre-filled syringe (medac, Germany; agent Sunny Medical), a once-weekly methotrexate for rheumatic and inflammatory diseases.

• Severe rheumatoid arthritis in selected adults with inadequate response to other antirheumatic therapy, including full-dose NSAIDs and usually at least one disease-modifying antirheumatic drugPopulation: AdultsIsrael Ministry of Health (drug registry)
• Polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs is inadequatePopulation: Children 3 years and older and adolescentsIsrael Ministry of Health (drug registry)
• Symptomatic control of severe recalcitrant disabling psoriasis not adequately responsive to other forms of therapyPopulation: AdultsIsrael Ministry of Health (drug registry)

• Hypersensitivity; severe liver impairment; alcohol abuse; severe renal impairment (creatinine clearance below 30 ml/min); pre-existing blood dyscrasias; serious, acute or chronic infections (e.g. tuberculosis, HIV); ulcers of the oral cavity and active gastrointestinal ulcer disease; pregnancy and breast-feeding; concurrent live vaccines.International label, same formulation · Israel Ministry of Health (drug registry)

• Nitrous oxidePotentiates the effect of methotrexate on folate metabolism (severe unpredictable myelosuppression, stomatitis); concomitant use should be avoided.Israel Ministry of Health (drug registry)
• Alcohol, hepatotoxic drugs (e.g. leflunomide) and haematotoxic drugs (e.g. azathioprine, retinoids, sulfasalazine)Regular alcohol and other hepatotoxic drugs increase the probability of hepatotoxicity; monitor with special care; pancytopenia and hepatotoxicity may increase when leflunomide is combined with methotrexate.Israel Ministry of Health (drug registry)

• Contraindicated in pregnancy in non-oncological indications; exclude pregnancy before starting. Low-dose exposure has been associated with spontaneous abortion in 42.5% of exposed pregnancies and major birth defects in 6.6% of live births.International label, same formulation · Israel Ministry of Health (drug registry)
• Methotrexate passes into breast milk; breast-feeding is contraindicated during treatment.International label, same formulation · Israel Ministry of Health (drug registry)

• Methotrexate: Folate analogue that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair and cellular replication; actively proliferating tissues are most sensitive (US label).